We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Protein in Brain Cell Cytoplasm Protects against Necrosis

By LabMedica International staff writers
Posted on 16 Nov 2011
High levels of the protein Nmnat 1 (nicotinamide mononucleotide adenylyl transferase 1) in the cytoplasm of brain cells protect these cells from damage caused by reduced blood flow and oxygen deprivation, conditions that can cause cerebral palsy in newborns.

Investigators at Washington University School of Medicine (St. More...
Louis, MO, USA) created a line of genetically engineered mice that overexpressed the gene for Nmnat 1 and exposed these animals to conditions that mimicked human infantile cerebral palsy.

They reported in the November 4, 2011, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that as early as six hours after experiencing oxygen deprivation the genetically engineered mice had strikingly less injury detected by MRI as compared to similarly treated normal control animals. Furthermore, the genetically engineered mice had markedly less injury in their hippocampus, cortex, and striatum than wild-type mice as assessed by loss of tissue volume seven days after injury.

“There are two types of injury in the developing brain from inadequate oxygen and blood flow,” said senior author Dr. David M. Holtzman professor of neurology at Washington University School of Medicine. “One is necrosis, where cells swell rapidly, burst, and die; another is apoptosis, where the cells shrink and die. We found that Nmnat1 prevents necrosis.”

“Under normal circumstances, the brain can handle a temporary disruption of either oxygen or blood flow during birth, but when they occur together and for long enough, long-term disability and death can result,” said Dr. Holtzman. “If we can use drugs to trigger the same protective pathway as Nmnat1, it may be possible to prevent brain damage that occurs from these conditions as well as from neurodegenerative diseases.”

Related Links:

Washington University School of Medicine



Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Blood Glucose Test Strip
AutoSense Test
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.